Holen Sie sich die Stockscreener-App
3.30
3.12%
0.09
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy" - MarketBeat
Perspective (CATX) Range: Posts a 8.41% Gain to $3.48 for the Current Session; Chart View - Vinanet
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11 - Bitget
Perspective Therapeutics Market Sentiment - Benzinga France
CATX Initiated by BMO Capital -- Rating Set to Outperform - GuruFocus
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital - Moomoo
BMO initiates Perspective Therapeutics stock at Outperform, $11 target By Investing.com - Investing.com India
BMO initiates Perspective Therapeutics stock at Outperform, $11 target - Investing.com
BMO Capital Initiates Perspective Therapeutics at Outperform - marketscreener.com
BMO Capital Initiates Coverage on CATX with Outperform Rating, H - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CATX Q1 2026 Earnings: Loss Beats Estimates by 17.25%, Shares Rise 3.23%Revenue Growth Outlook - Vinanet
CATX Maintained by B of A Securities -- Price Target Lowered to $5.00 - GuruFocus
Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00 - MarketBeat
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
Q3 EPS Forecast for Perspective Therapeutics Lifted by Analyst - MarketBeat
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 - marketscreener.com
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
Perspective Therapeutics (CATX) Stock Price, News & Analysis - marketbeat.com
Perspective Therapeutics (CATX): Millennium group reports over 5% beneficial stake - Stock Titan
Analysts Set Expectations for Perspective Therapeutics Q1 Earnings - MarketBeat
RBC Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics, Inc. (CATX) Latest Stock News & Headlines - Yahoo Finance
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Piper Sandler cuts Perspective Therapeutics price target on timing By Investing.com - Investing.com Australia
Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says - marketscreener.com
Piper Sandler cuts Perspective Therapeutics price target on timing - Investing.com
CATX Maintained by Piper Sandler -- Price Target Lowered to $14. - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $14.00 at Piper Sandler - MarketBeat
Perspective Therapeutics Price Target Cut to $14.00/Share From $16.00 by Piper Sandler - Moomoo
Perspective Therapeutics (CATX) Climbs 4.7% to $3.14 as Buyers Defend Key SupportValue ETF - Vinanet
Perspective Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports Q2 Results and Pipeline Progress - TipRanks
Perspective Therapeutics Q2 FY26 net loss widens to $26.8 million - Bitget
Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results - MarketBeat
Form 8K Perspective Therapeutics Inc For: 10 August By Investing.com - Investing.com Australia
Perspective Therapeutics Q2 EPS beats estimates as sales miss consensus - scanx.trade
Perspective Therapeutics: Q2 Earnings Snapshot - AOL.com
Perspective Therapeutics Reports $26.8 Million Q2 Net Loss - Quiver Quantitative
Perspective Therapeutics (CATX) expands cash to $236.9M while losses widen - Stock Titan
Perspective Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Perspective Therapeutics (NYSE: CATX) grows cash to $237M while advancing Phase 3-ready pipeline - Stock Titan
Perspective Therapeutics Advances VMT-α-NET Toward Phase 3 as Pipeline and Manufacturing Expansion Progresses - Quiver Quantitative
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results - The Manila Times
Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MSN Money - MSN
Perspective Therapeutics Inc (CATX) Stock News Today - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
State Street Corporation (NYSE: CATX) reports 6.05M-share, 5.3% stake in Perspective - Stock Titan
Perspective Therapeutics (CATX) to Announce Earnings on Wednesday - MarketBeat
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year? - Yahoo Finance
Perspective Therapeutics (CATX) Gets a Buy from Wedbush - The Globe and Mail
Perspective Therapeutics Advances 212Pb Radiopharmaceutical Oncology Platform - The Globe and Mail
Perspective Therapeutics updates corporate presentation, highlights progress across 212Pb radiopharmaceutical portfolio - TradingView
Perspective Therapeutics (NYSE: CATX) details 212Pb radiopharma pipeline - Stock Titan
Seven Fleet Capital Management LP Buys New Stake in Perspective Therapeutics, Inc. $CATX - MarketBeat
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP - MarketBeat
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results - Yahoo Finance
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo! Finance Canada
BlackRock (CATX holder) discloses 6.8% beneficial stake in Perspective Therapeutics - Stock Titan
Perspective Therapeutics Inc (CATX) Balance Sheet - TradingKey
1.16%
0.29%
Kapitalisierung:
|
Volumen (24h):